Payment overview · 2025
General Payments
$16,727.30
69 reported records · 16 companies
Healthcare provider profile · identity verified
Robert Anthony Leonardi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · WEST COLUMBIA, SC · NPI 1013182898
Verified facts
What the public records show
CMS Open Payments records show Robert Anthony Leonardi, M.D. received $16,727.30 in general payments during 2025 across 69 reported records.
Edwards Lifesciences Corporation accounted for 75.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 402 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $12,686.03 | 75.8% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $2,117.39 | 12.7% | 16 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $695.84 | 4.2% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $583.05 | 3.5% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$176.32 | 1.1% | 9 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $148.29 | 0.9% | 6 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $80.79 | 0.5% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $43.78 | 0.3% | 2 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $36.70 | 0.2% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.00 | 0.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.08 | 0.2% | 1 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $21.65 | 0.1% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $21.08 | 0.1% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $19.83 | 0.1% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $19.11 | 0.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.36 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $10,312.50 | 3 |
| Travel and Lodging | $4,113.45 | 15 |
| Food and Beverage | $2,301.35 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $11,351.00 | 5 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $1,784.27 | 9 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $354.05 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $316.50 | 2 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $249.17 | 5 | 2025 |
Source payment records
|
|||||
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $204.46 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $144.35 | 4 | 2025 |
Source payment records
|
|||||
| Baylis Medical Company Radiofrequency Puncture Generator Normalized: baylis medical company radiofrequency puncture generator |
Device | Boston Scientific Corporation | $140.30 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $129.67 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $126.25 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $120.90 | 4 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $80.79 | 2 | 2025 |
Source payment records
|
|||||
| OPTOWIRE Normalized: optowire |
Device | CARDIVA MEDICAL, INC. | $43.78 | 2 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $39.91 | 3 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $36.70 | 2 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $36.21 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $33.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.08 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER Normalized: amplatzer |
Device | Abbott Laboratories | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER TALISMAN Normalized: amplatzer talisman |
Device | Abbott Laboratories | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| AtriCure cryoICE Cryoablation System (CRYO2) Normalized: atricure cryoice cryoablation system cryo2 |
Device | AtriCure, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| EPI-EASE EPICARDIAL ACCESS SYSTEM Normalized: epi ease epicardial access system |
Device | AtriCure, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $14.77 | 2 | 2025 |
Source payment records
|
|||||
| SELECTSECURE Normalized: selectsecure |
Device | Medtronic, Inc. | $8.11 | 1 | 2025 |
Source payment records
|
|||||
| TYRX Normalized: tyrx |
Device | Medtronic, Inc. | $7.40 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $3.94 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
402 | 97 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 402 | 97 |
| Carvedilol | Carvedilol | 363 | 119 |
| Metoprolol Succinate | Metoprolol Succinate | 323 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 310 | 106 |
| Losartan Potassium | Losartan Potassium | 253 | 87 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 76 |
| Furosemide | Furosemide | 173 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 145 | 59 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 108 | 34 |
| Brilinta | Ticagrelor | 105 | 25 |
| Entresto | Sacubitril/Valsartan | 105 | 23 |
| Lisinopril | Lisinopril | 102 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 86 | 22 |
| Spironolactone | Spironolactone | 74 | 28 |
| Amiodarone Hcl | Amiodarone Hcl | 69 | 25 |
| Ezetimibe | Ezetimibe | 61 | 24 |
| Terazosin Hcl | Terazosin Hcl | 46 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 18 |
| Amoxicillin | Amoxicillin | 39 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 13 |
| Warfarin Sodium | Warfarin Sodium | 39 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 16 |
| Potassium Chloride | Potassium Chloride | 38 | 18 |
| Flecainide Acetate | Flecainide Acetate | 36 | suppressed |
| Xarelto | Rivaroxaban | 33 | 13 |
| Valsartan | Valsartan | 31 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Dofetilide | Dofetilide | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16,727.30 · 69 records | Edwards Lifesciences Corporation | AMPLATZER, AMPLATZER TALISMAN, ATRICLIP LAA EXCLUSION SYSTEM, AVVIGO Guidance System, AtriCure cryoICE Cryoablation System (CRYO2), Baylis Medical Company Radiofrequency Puncture Generator, CAMZYOS, CARTO 3, CLOTTRIEVER BOLD CATHETER, COREVALVE EVOLUT R, DIAMONDBACK CORONARY, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), EPI-EASE EPICARDIAL ACCESS SYSTEM, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FLOWTRIEVER, KENGREAL, LINQ II, LifeVest, MITRACLIP, MYNX CONTROL VENOUS, NAVITOR, ONPATTRO, OPTOWIRE, PASCAL, SAPIEN 3 Ultra RESILIA, SELECTSECURE, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TRICLIP, TYRX, ULTREON, WATCHMAN FLX, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error